NASDAQ · Biotechnology

CBIO (CBIO) Stock

$16.84 +2.50% NASDAQ: CBIO Healthcare

Valuation

MetricValue
Price$16.84
Market Cap$625.50M
P/E Ratio-6.03
P/B Ratio3.28
P/S Ratio41.17
EPS (TTM)$0.00
52-Week High$27.41
52-Week Low$8.72
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-75.86%
ROA-64.17%
ROCE-75.37%
Gross Margin100.00%
Operating Margin-13.73%
Net Margin-13.64%
Debt/Equity0.01
Current Ratio6.58

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$0$0$0$11.0M
Operating Profit$-63.0M$-47.0M$-39.0M$-50.0M$-153.0M
Net Profit$-63.0M$-47.0M$-37.0M$-49.0M$-154.0M
EPS$-1.23$-0.89$-0.58$-1.40$-14.78
Op Margin-5470.7%-63204.4%-392752.9%-1407.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$94.0M$52.0M$45.0M$36.0M$240.0M
Total Liabilities$13.0M$9.0M$7.0M$51.0M$37.0M
Cash$90.0M$48.0M$42.0M$35.0M$213.0M
Borrowings$2.0M$1.0M$1.0M$37.0M$2.0M

Latest News

Crescent Biopharma Closes $143.7 Million Public Offering MT Newswires · Jul 16, 2026 Crescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares GlobeNewswire · Jul 16, 2026 Crescent Biopharma Prices $125 Million Common, Warrant Offering MT Newswires · Jul 15, 2026 Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants GlobeNewswire · Jul 15, 2026 Crescent Biopharma Launches Offering of Common Shares, Warrants MT Newswires · Jul 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-57.0M$-46.0M$-35.0M$-31.0M$-72.0M
Investing Cash Flow$0$0$0$0$-74.0M
Financing Cash Flow$0$0$0$0$323.0M
Net Cash Flow$-47.0M$-42.0M$-6.0M$-31.0M$179.0M
Free Cash Flow$-58.0M$-47.0M$-35.0M$-31.0M$-72.0M

Valuation & Return Ratios

MetricValue
PEG Ratio
EV / EBITDA
FCF Yield-30.34%
Quick Ratio13.78
Interest Coverage-76.50
Return 1Y29.21%
Return 3Y-89.62%
Return 5Y-106.86%

Ownership

Insiders Held0.44%
Institutions Held77.62%
Institutions Float Held77.96%
Institutional HolderSharesReport Date
FMR, LLC4,133,5142026-03-31
BVF Inc.2,748,7632026-03-31
Fairmount Funds Management LLC2,747,8662026-03-31
Venrock Adviser, LLC2,133,5762026-03-31
FCPM III Services B.V.1,677,8522026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARMPArmata Pharmaceuticals, Inc. $4.64 -0.43% -0.60 $170.34M 0.00%
CCCC $3.52 -0.85% -2.54 $389.20M 0.00%
CGEN $2.27 -4.83% 7.21 $214.16M 0.00%
HIND $2.17 +0.23% -0.44 $15.23M 0.00%
HRTX $0.51 +3.06% -7.08 $96.80M 0.00%

About CBIO

CBIO is led by CEO Joshua T. Brumm, employs 41 people, headquartered in US, publicly traded since 2014.

CBIO stock trades at $16.84 with a market capitalization of $625.50M. The stock is valued at a price-to-earnings (P/E) ratio of -6.03, price-to-book of 3.28, price-to-sales of 41.17. Over the past 52 weeks the stock has ranged between $8.72 and $27.41, and currently trades 38.6% below its 52-week high.

On profitability, CBIO generates a return on equity (ROE) of -75.86%, return on capital employed of -75.37%, an operating margin of -13.73%, a net profit margin of -13.64%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides